Quantitative Evaluation of in Vivo Target Efficacy of Anti-tumor Agents via an Immunofluorescence and EdU Labeling Strategy

Yujun He, Jin Wen, Qinghua Cui, Fangfang Lai, Dali Yin, Huaqing CuiFrontiers in Pharmacology 2018 · DOI

TL;DR

This paper introduces a novel, quantitative method for evaluating anti-cancer drug efficacy in vivo. By combining EdU labeling to identify proliferating cells with immunofluorescence for target protein detection, researchers can precisely measure drug effects within specific tumor regions, overcoming limitations of traditional methods.

What Problem Does This Paper Address?

Evaluating the effectiveness of new anti-cancer drugs in living organisms (in vivo) is a critical step in drug development. Current standard methods, like Western blotting, offer only semi-quantitative protein expression analysis and struggle to differentiate the efficacy of drugs with similar mechanisms of action. Immunofluorescence and immunohistochemistry can visualize protein expression but lack precise quantitative standards. This makes it challenging to accurately compare drug performance and understand how they affect specific cellular processes within a tumor. The authors aim to bridge this gap by developing a more sensitive and quantitative approach that leverages spatial information within the tumor.

Methods

The core of this paper is a refined protocol that combines two key techniques:

  • EdU Labeling: This method uses a modified nucleoside (EdU) that is incorporated into newly synthesized DNA during cell proliferation. EdU can then be detected using a "click chemistry" reaction, which allows for fluorescent labeling of actively dividing cells. The authors optimized the dosage and timing of EdU administration to ensure robust labeling of proliferating tumor cells.
  • Immunofluorescence (IF): This technique uses antibodies tagged with fluorescent markers to detect specific proteins within cells.

The novelty lies in the integration and spatial analysis of these two methods. Tumor tissues are first labeled with EdU to delineate proliferating (EdU-positive) and non-proliferating (EdU-negative) areas. Then, immunofluorescence is used to visualize the expression of target proteins. By analyzing protein expression specifically within these defined EdU-positive and EdU-negative regions, the researchers can quantitatively assess how drug treatment affects both cell proliferation and the expression of target proteins in a spatially resolved manner. This allows for a more precise comparison of drug efficacy between treated and control groups.

Datasets

The study utilized established human cancer cell lines (H460, MCF-7) and mouse cancer cell lines (MC38) to create xenograft tumors in mice. These tumors served as the biological "datasets" for evaluating the developed methodology. No new benchmark datasets were introduced.

Key Insights and Ideas

  • Spatial Resolution is Key: The paper strongly emphasizes that analyzing protein expression within specific, functionally defined regions of a tumor (proliferating vs. non-proliferating) provides much richer and more accurate information than analyzing the entire tumor homogenate.
  • EdU as a Spatial Standard: EdU labeling effectively acts as a spatial "map" of tumor proliferation, serving as a crucial internal control or standard for quantitative analysis of protein expression.
  • Concurrent Labeling is Possible: The mild conditions required for EdU labeling allow it to be performed concurrently with immunofluorescence, enabling the visualization of both proliferation and protein expression in the same tissue section. However, immunohistochemistry methods that involve enzymatic reactions (like DAB) can interfere with EdU labeling.
  • Diverse Protein Localization: The study found that among 15 cancer-related proteins examined, most were localized either predominantly in proliferating or non-proliferating areas, highlighting the importance of spatial context for understanding protein function in cancer.

Key Results

  • Optimized EdU Protocol: The authors established an optimal EdU dosage (50 mg/kg) and administration time (8 hours prior to sacrifice) for xenograft tumor models.
  • Successful Combination: The EdU labeling and immunofluorescence protocols were successfully combined, producing high-quality merged images that clearly showed the overlap between proliferating areas and specific protein expressions.
  • Quantitative Efficacy Measurement: The method allowed for the precise quantification of changes in protein expression and cell proliferation. For example, BKM120 treatment reduced cell proliferation by 78.4% and phosphorylated Akt expression by 93.4% in MCF-7 xenografts. PX-478 treatment inhibited HIF-1α expression by 98.6% and reduced tumor growth by 80.3% in H460 xenografts.
  • High Sensitivity: The method is described as exhibiting high sensitivity, allowing for the detection of subtle changes in protein expression.

Limitations and Future Work

  • Immunohistochemistry Interference: The paper notes that traditional immunohistochemistry methods using enzymatic reactions (like DAB) can interfere with EdU labeling, limiting its applicability in such combined protocols.
  • Image Analysis Platform: While the study used Image-Pro Plus for image analysis, the authors suggest that this method can be integrated with other advanced imaging analysis platforms (e.g., high-content screening) for even more comprehensive drug discovery projects.
  • Broader Application: The authors propose that this quantitative strategy can be applied to evaluate the efficacy of a wider range of anti-tumor agents, especially those with similar modes of action, by providing a more sensitive and comparative analysis. Future work could involve applying this method to a broader panel of drugs and cancer types.

Summary updated

Abstract

Current methods used to evaluate <i>in vivo</i> target efficacy of selected compound include western blot to semi-quantitatively analyze protein expression. However, problems arise as it is difficult to compare <i>in vivo</i> target efficacy of anti-tumor agents with the same mode of action. It is therefore desirable to develop a protocol that can quantitatively display <i>in vivo</i> target efficacy while also providing other useful information. In this study EdU labeling was used to mark out the proliferating area. The tumor tissue was accordingly divided into proliferating and non-proliferating areas. Fifteen tumor related proteins were stained by immunofluorescence and were found to express in either the proliferating or non-proliferating areas. This allows the quantitative analysis of protein expressions within the precise area. With simple image analysis, our method gave precise percent changes of protein expression and cell proliferation between the drugs treated group and the control group. Additional information, such as, the status of protein expression can also be obtained. This method exhibits high sensitivity, and provides a quantitative approach for <i>in vivo</i> evaluation of target efficacy.
BibTeX
@inproceedings{he2018quantitative,
  author = {Yujun He and Jin Wen and Qinghua Cui and Fangfang Lai and Dali Yin and Huaqing Cui},
  title = {{Quantitative Evaluation of in Vivo Target Efficacy of Anti-tumor Agents via an Immunofluorescence and EdU Labeling Strategy}},
  booktitle = {Frontiers in Pharmacology},
  year = {2018},
  doi = {10.3389/fphar.2018.00812},
}
Figure